Federal Grant Award Summary

Yale University received a $1.05M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support research on harnessing myeloid cell ontogeny to prevent melanoma brain metastasis. The award, dated July 1, 2026, will be performed at Yale's New Haven, Connecticut location through June 30, 2029. This three-year research initiative aligns with the DHA's broader portfolio of hypothesis-driven biomedical research designed to advance healthcare solutions for military service members and the general public, with particular emphasis on cancer immunotherapy and precision medicine approaches.

The funded research will deliver translational science and biomedical research services focused on understanding myeloid cell development and function as a mechanism to prevent the spread of melanoma to the brain. As part of the Military Medical Research and Development program's two-tier competitive review process, this project was evaluated for both technical merit and military relevance before funding authorization. The grant represents Yale's established capacity in delivering complex biomedical research and oncology-focused investigations consistent with the institution's active federal research portfolio across the National Institutes of Health, National Science Foundation, and Department of Defense funding mechanisms.